RecruitingEarly Phase 1NCT06886516

Apixaban in Thrombocytopenia

ADAPTiON: Apixaban Dose Adjustment in Patient With Thrombocytopenia in ONcology

Sponsor

Rushad Patell

Enrollment

30 participants

Start Date

Feb 28, 2025

Study Type

INTERVENTIONAL

Conditions

Thrombocytopenia Deep Vein Thrombosis Pulmonary Embolism and Thrombosis Recurrent Venous Thromboembolism

Summary

This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether apixaban — a blood thinner commonly used to treat blood clots — is safe and effective for treating blood clots (deep vein thrombosis or pulmonary embolism) in cancer patients who also have low platelet counts (thrombocytopenia), a condition that normally makes blood thinners risky to use. **You may be eligible if...** - You are 18 or older - You have an active cancer diagnosis - You were recently diagnosed with a blood clot (deep vein thrombosis or pulmonary embolism) within the past 28 days - Your platelet count is below 75,000 per milliliter - You have no active or recent major bleeding - You have no known brain metastases - Your kidneys are functioning adequately **You may NOT be eligible if...** - You have had a serious bleeding episode in the past 12 months - Your platelet count does not respond to transfusions - You have brain metastases - You are pregnant or breastfeeding - You are taking certain medications that interact with apixaban Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.